Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP795056.RApB4W2yQm3HnddeWd657OvmM3Grji-o-u1RfeQpgUUxY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP795056.RApB4W2yQm3HnddeWd657OvmM3Grji-o-u1RfeQpgUUxY130_assertion type Assertion NP795056.RApB4W2yQm3HnddeWd657OvmM3Grji-o-u1RfeQpgUUxY130_head.
- NP795056.RApB4W2yQm3HnddeWd657OvmM3Grji-o-u1RfeQpgUUxY130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP795056.RApB4W2yQm3HnddeWd657OvmM3Grji-o-u1RfeQpgUUxY130_provenance.
- NP795056.RApB4W2yQm3HnddeWd657OvmM3Grji-o-u1RfeQpgUUxY130_assertion evidence source_evidence_literature NP795056.RApB4W2yQm3HnddeWd657OvmM3Grji-o-u1RfeQpgUUxY130_provenance.
- NP795056.RApB4W2yQm3HnddeWd657OvmM3Grji-o-u1RfeQpgUUxY130_assertion SIO_000772 22890388 NP795056.RApB4W2yQm3HnddeWd657OvmM3Grji-o-u1RfeQpgUUxY130_provenance.
- NP795056.RApB4W2yQm3HnddeWd657OvmM3Grji-o-u1RfeQpgUUxY130_assertion wasDerivedFrom befree-20140225 NP795056.RApB4W2yQm3HnddeWd657OvmM3Grji-o-u1RfeQpgUUxY130_provenance.
- NP795056.RApB4W2yQm3HnddeWd657OvmM3Grji-o-u1RfeQpgUUxY130_assertion wasGeneratedBy ECO_0000203 NP795056.RApB4W2yQm3HnddeWd657OvmM3Grji-o-u1RfeQpgUUxY130_provenance.